Search Results
46 Results Found for “transcranial magnetic stimulation”
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1Â Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
The 11th Congress of the European Academy of Neurology (EAN) delivered ground-breaking insights across neurology, showcasing how precision medicine is reshaping clinical practice. Taken from the EAN Highlights and Breaking news session presented 24 June 2025 (PLEN03), touchNEUROLOGY summarizes the key highlights across dementia, headache, movement disorders, cerebrovascular and neuromuscular diseases.
"Continued support for research, and for the patients themselves, is absolutely critical. I’m grateful for the opportunity to help bring some of this work to light." Dr Anissa Abi-Dargham is Chair of Psychiatry and Behavioral Health at the Renaissance ...
Despite being one of the most common serious psychiatric disorders, major depression remains difficult to treat with only 30-50% of patients achieving remission from monotherapy or talk therapy, however many promising new antidepressants are currently under investigation. We were delighted ...
Neuromodulation is a recent technique that has increasingly been used for the abortive and preventive treatment of migraine and other primary headache disorders.1Â It has previously been found to be helpful in the treatment of other neurological illnesses, such as ...
XEN1101: A Novel Potassium Channel Modulator for the Potential Treatment of Focal Epilepsy in Adults
Despite the use of various concurrent antiseizure medications (ASMs), over 30% of patients with focal onset seizures have persistent, uncontrolled seizures.1 Hence, the search for new ASMs with better efficacy and tolerability is continuing. Voltage-gated potassium ion channels (Kv) repolarize neuronal ...
It cannot be seen, cannot be felt, cannot be heard, cannot be smelt. It lies behind stars and under hills, and empty holes it fills. It comes first and follows after, ends life, kills laughter. The Hobbit. JRR Tolkien ‘Darkness’ ...
Parkinson’s disease (PD) is a progressive, neurodegenerative movement disorder and the second most common neurodegenerative disorder in the United States.1 In 2020, approximately 930,000 people in the United States aged 45 years and older developed the disease, and this number is expected ...
Following approval in Europe in 2015 and in the USA in 2017,1 and its subsequent introduction, safinamide has become established as an effective and well-tolerated add-on to levodopa treatment in Parkinson’s disease (PD). Despite the extensive clinical trial data and a ...
Parkinson’s disease (PD) is classically defined as a movement disorder with key features including motor disturbances such as tremor, rigidity, akinesia and postural instability. Non-motor symptoms are also present, and can include disturbances in autonomic function, sleep, cognition, sensory ...
Parkinson’s disease (PD) is a multifaceted neurodegenerative disease that progressively affects individuals’ mobility. In addition to the cumulative motor disability, a plethora of non-motor symptoms (NMS-PD) can be encountered at different stages of the disease. Some of these NMS-PD ...
Headache is the second most common reason children seek neurological care in the USA.1 Migraine can affect children of all ages, and by the age 10, it affects more than 5% of children in the USA.1 Before puberty, it affects both boys ...
Proceedings of a symposium presented at the 13th European Congress of Epileptology, Vienna, 26th August 2018, sponsored by LivaNova. The management of patients with drug-resistant epilepsy (DRE) or treatment-resistant depression (TRD) remain serious challenges. Both conditions are common; epilepsy is believed ...
The 4th Congress of the European Academy of Neurology (EAN) was held in Lisbon, Portugal. This article will discuss some of the key presentations on the subject of Parkinson’s disease (PD), which is the second most common movement disorder ...
Welcome to the latest edition of European Neurological Review, which features a wide range of topical articles covering several areas of neurology. We would like to begin by introducing our new Editor-in-Chief, Cris Constantinescu, whose knowledge and expertise will be ...
Chronic pain affects millions of people around the globe. Current consensus considers chronic pain as a disease that arises from maladaptive changes within the central nervous system. Chronic pain poses a huge impact on affected individuals, societies, and health care ...
Migraine is the sixth most common form of disability globally that affects young, otherwise healthy subjects at the peak of their productive years.1 The management of chronic or refractory migraine with traditional pharmacological approaches can often prove challenging and unsatisfactory. ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
